¹³¹I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma

Bibliography

• CBTRUS: Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Published by the Central Brain Tumor Registry of the United States. (2005).
   Google Scholar
• GIESE A, BJERKVIG R, BERENS ME, WESTPHAL M: Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. (2003) 21:1624-1636.
   PubMed Web of Science ®Google Scholar
• COMBS SE, GUTWEIN S, THILMANN C, HUBER P, DEBUS J, SCHULZ-ERTNER D: Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J. Neurooncol. (2005) 74:167-171.
   PubMed Web of Science ®Google Scholar
• COMBS SE, AHMADI R, SCHULZ-ERTNER D, THILMANN C, DEBUS J: Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J. Neurooncol. (2005) 71:319-323.
   PubMed Web of Science ®Google Scholar
• WALLNER KE, GALICICH JH, KROL G, ARBIT E, MALKIN MG: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. (1989) 16:1405-1409.
   PubMed Web of Science ®Google Scholar
• RAMPLING R: Modern aspects of radiation therapy for glial tumours of the brain. Forum (Genova) (1998) 8:289-301.
   PubMedGoogle Scholar
• BURTON E, PRADOS M: Management of primary malignant brain tumors in adults. In: American Cancer Society Atlas of Clinical Oncology Brain Cancer. Steele GD, Phillips TL, Chabner BA (Eds), BC Decker, London, UK (2002):262-278.
   Google Scholar
• DEANGELIS LM: Brain tumors. N. Engl. J. Med. (2001) 344:114-123.
   PubMed Web of Science ®Google Scholar
• CHO KH, HALL WA, GERBI BJ, HIGGINS PD, MCGUIRE WA, CLARK HB: Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. (1999) 45:1133-1141.
   PubMed Web of Science ®Google Scholar
• HALL WA, DJALILIAN HR, SPERDUTO PW et al.: Stereotactic radiosurgery for recurrent malignant gliomas. J. Clin. Oncol. (1995) 13:1642-1648.
   PubMed Web of Science ®Google Scholar
• COMBS SE, THILMANN C, EDLER L, DEBUS J, SCHULZ-ERTNER D: Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution. J. Clin. Oncol. (2005) 23:8863-8869.
   PubMed Web of Science ®Google Scholar
• BRADA M, CRUICKSHANK G: Radiosurgery for brain tumors. Br. Med. J. (1999) 318:411-412.
   PubMed Web of Science ®Google Scholar
• CURRAN WJ JR, SCOTT CB, WEINSTEIN AS et al.: Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J. Clin. Oncol. (1993) 11:857-862.
   PubMed Web of Science ®Google Scholar
• CHANG SM: Systemic chemotherapy of central nervous tumors. In: American Cancer Society Atlas of Clinical Oncology Brain Cancer. Steele GD, Phillips TL, Chabner BA (Eds), BC Decker, London, UK (2002):193-210.
   Google Scholar
• SCHNEIDER SW, LUDWIG T, TATENHORST L et al.: Glioblastoma cells release factors that disrupt blood brain barrier features. Acta Neuropathol. (Berlin) (2004) 107:272-276.
   PubMed Web of Science ®Google Scholar
• YUNG WK, PRADOS MD, YAYA-TUR R et al.: Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. (1999) 17:2762-2771.
   PubMed Web of Science ®Google Scholar
• STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352:987-996.
   PubMed Web of Science ®Google Scholar
• QUINN JA, DESJARDINS A, WEINGART J et al.: Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. (2005) 23:7178-7187.
   PubMed Web of Science ®Google Scholar
• WESTPHAL M, HILT DC, BORTEY E et al.: A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol. (2003) 5:79-88.
   PubMed Web of Science ®Google Scholar
• EPSTEIN AL, CHEN D, ANSARI A et al.: Radioimmunodetection of necrotic lesions in human tumors using I-131 labeled TNT-1 F(ab’)2 monoclonal antibody. Antibody Immunoconj. Radiopharm. (1991) 4:151-161.
   Google Scholar
• COOPER EH: The biology of cell death in tumours. Cell Tissue Kinet. (1973) 6:87-95.
   PubMedGoogle Scholar
• PATEL SJ, SHAPIRO WR, LASKE DW et al.: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery (2005) 56:1243-1253.
   PubMed Web of Science ®Google Scholar
• CHEN S, YU L, JIANG C et al.: Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. (2005) 23:1538-1547.
   PubMed Web of Science ®Google Scholar
• EPSTEIN AL, KHAWLI LA, CHEN FM, HU P, GLASKY MS, TAYLOR CR: Tumor necrosis imaging and treatment of solid tumors. In: Handbook of Targeted Delivery of Imaging Agents. Torchillin VP (Ed.), CRC Press, Boca Raton, FL, USA (1995):259-288.
   Google Scholar
• ANDERSON PM, WISEMAN GA, LEWIS BD et al.: A Phase I safety and imaging study using radiofrequency ablation (RFA) followed by 131I-chTNT-1/B radioimmunotherapy adjuvant treatment of hepatic metastases. Cancer Ther. (2003) 1:297-306.
   Google Scholar
• KHAWLI LA, MIZOKAMI MM, ZHEN L et al.: Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother. Radiopharm. (2002) 17:359-370.
   PubMed Web of Science ®Google Scholar
• PATEL SJ, SPICER K, VANTASSEL P et al.: Phase I results of intra-tumoral infusion of 131I-chTNT-1/B in the treatment of recurrent malignant gliomas. Proceedings of the 35th American Society of Clinical Oncology. Atlanta, USA (15 – 18 May 1999):550.
   Google Scholar
• WESSELS B, JENSEN R, PATEL S et al.: Image fusion and patient specific dosimetry for tumor response and toxicity evaluation in patients with glioma undergoing radionuclide therapy. Neurooncol. (2003) 5:343.
   Google Scholar